Loading stock data…
DH
$0.99+0.03 (+3.47%)
Market ClosedLast close May 1
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Definitive Healthcare Corp. in the Healthcare sector is trading at $0.99. The stock is currently near its 52-week low of $0.90, remaining 61.9% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why DH maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.99
Potential Upside
5%
Whystock Fair Value$1.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$104.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.42%
Volume
Today's trading volume
234,528
Recent News
Docebo Inc. (DCBO) Reports Next Week: Wall Street Expects Earnings Growth
Docebo (DCBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Definitive Healthcare Corp. (DH) to Report a Decline in Earnings: What to Look Out for
Definitive Healthcare (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Definitive Healthcare (DH) Earnings Transcript
Kevin D. Coop: Thank you, Jonathan, and thanks to all of you for joining us this afternoon to review Definitive Healthcare Corp.'s fourth quarter 2025 financial results. On today's call, I will provide highlights from our fourth quarter performance, review the operational progress we have made in 2025, and outline our key strategic priorities for 2026. Let me begin by reviewing our financial results for the fourth quarter, which were at or above the high end of our guidance ranges on both the top and bottom line.
Definitive Healthcare Corp. Q4 2025 Earnings Call Summary
Moby summary of Definitive Healthcare Corp.'s Q4 2025 earnings call
Definitive Healthcare Corp (DH) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges ...
Despite a slight revenue decline, Definitive Healthcare Corp (DH) focuses on data differentiation and strategic partnerships to enhance customer retention and satisfaction.